Robert Schoevers

Robert A. Schoevers is an academic psychiatrist whose recent research focuses on novel, rapid-acting treatments for treatment-resistant depression (TRD). He has been involved in clinical programmes evaluating oral esketamine through both open-label effectiveness/tolerability studies and double-blind, randomized, placebo-controlled trials with open-label extensions. In addition to pharmacotherapy trials, Schoevers has contributed to clinical research on psilocybin-assisted interventions, including single-dose treatment studies, qualitative investigations of patient perspectives, and analyses of the phenomenological role of the psychedelic experience in therapeutic outcomes.

His work spans safety and tolerability assessment, trial design for psychedelic and glutamatergic agents, and integration of qualitative patient-reported outcomes with quantitative clinical endpoints. Through these contributions, Schoevers has helped advance the evidence base for implementing rapid-acting antidepressant strategies in specialised clinical settings and informed best practices for assessing both clinical efficacy and experiential factors relevant to psychedelic-assisted therapy.